SEATTLE, April 30, 2012 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV) has pleasure in announcing the appointment of Mark Reddish to the Board of Directors. Mark is currently Vice President of Development at TapImmune and is responsible for developing the Company’s product pipeline. He was formerly Vice President of Research & Development and Principal Investigator, Biodefense at ID Biomedical, Bothell, WA, prior to the acquisition of the company by Glaxo SmithKline. At Biomira Inc, Edmonton, Alberta (now renamed Oncothyreon, Seattle) he was responsible for preclinical development of their cancer vaccine program where he led the early research and clinical development of both Theratope and Stimuvax. Stimuvax is currently in late Stage 3 Clinical Trials partnered with Merk KGa/ Serono. Mark’s corporate experience also extends to Baxter Healthcare and Bayer AG. He has a degree in Biology from Bates College and did graduate studies in Microbiology/Immunology at University of Massachusetts.
